Singapore-based biotech firm Engine Biosciences raises SGD 57 million to advance cancer treatment
Summary
Established in 2016, Engine Biosciences applies machine learning and other experimental systems to genomics for drug discoveries and the development of specific therapies. “Because our platform can continuously improve, repeat, and scale to discover and develop new products for each disease and patient subpopulation we pursue, we see the possibility of life-changing impacts by powering precision medicine into the next generation,” Lu added. High-ranking genes from the tests are prioritized for drug discovery and development, while the data from the experiment also serves to improve the company’s machine learning algorithms. Our platform gives us the ability to assemble a broad portfolio of compelling and unique assets that are diversified in risk and expansive in upside,” said Lu. Engine Biosciences has also cooperated with partners including biotech and pharma companies in the US, which can access the startup’s research of diseases for drug development.